IP Library Granted Patent US 7,906,149
Granted Patent B2
US 7,906,149 · App. 11/754,052 · Granted Mar 15, 2011

Method for treating allergic dermatitis

Assignee: Boval Company, L.P.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,149
App. No.
11/754,052
Granted
Mar 15, 2011
Kind
B2
Abstract

A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.

Claims (33)

1. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting essentially of from about 2 to about 6 percent by weight of albumin for a sufficient amount of time to enable the albumin to provide a localized anti-inflammatory effect and

removing the albumin from the affected area;

wherein the composition minimizes the removal of protective lipids from the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

2. The method of claim 1 , wherein the composition is a liquid, gel, cream, lotion, paste, ointment, foam, spray, mist, or aerosol to the affected area.

3. The method of claim 1 , wherein the composition is provided as a coating on, or a filler in a dressing, substrate or patch.

4. The method of claim 1 , wherein the albumin is a serum albumin.

5. The method of claim 1 , wherein the composition further consisting essentially of a pharmaceutically active ingredient.

6. The method of claim 5 , wherein the pharmaceutically active ingredient is selected from the group consisting of an analgesic, an antiasthmatic, an antimicrobial, an antipruritic, an antihistamine, an anti-inflammatory, an anti-skin wrinkling agent, a tanning active, a vasoconstrictor, a vasodilator, a vitamin substance, and mixtures thereof.

7. The method of claim 1 , wherein the composition further consisting essentially of a drying agent.

8. The method of claim 1 , wherein the composition further consisting essentially of a film former.

9. The method of claim 1 , where the oleoresin is urushiol.

10. The method of claim 1 , wherein the oleoresin is isosolenopsin A.

11. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting of by weight from 2 to 6% of albumin, from 0.05 to 0.1% of a chelating agent, from 0.05 to 0.1% of a preservative, from 0.5 to 2% of a thickener, from 2 to 6% of a co-solvent, from 1.0 to 4.0% of an humectant, and a diluent, and

removing the composition from the affected area;

wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

12. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting of by weight from 2 to 6% of a bovine serum albumin, from 0.05 to 0.1% of a chelating agent, from 0.05 to 0.1% of a preservative, from 0.5 to 2% of a thickener, from 2 to 6% of a co-solvent, from 1.0 to 4.0% of an humectant, and a diluent, and

removing the composition from the affected area;

wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

13. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting of by weight from 2 to 6% of albumin, from 0.05 to 0.1% of disodium ethylenediamine tetraacetate, from 0.05 to 0.1% of methyl paraben, from 0.5 to 2% of hydroxypropylcellulose, from 2 to 6% of polyethylene glycol, from 1.0 to 4.0% of glycerine, and water, and

removing the composition from the affected area;

wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

14. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting of by weight from 2 to 6% of bovine serum albumin, from 0.05 to 0.1% of disodium ethylenediamine tetraacetate, from 0.05 to 0.1% of methyl paraben, from 0.5 to 2% of hydroxypropylcellulose, from 2 to 6% of polyethylene glycol, from 1.0 to 4.0% of glycerine, and water, and

removing the composition from the affected area;

wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

15. A method for treating oleoresin induced allergic dermatitis comprising:

topically contacting an affected area with a composition consisting essentially of from about 2 to about 6 percent by weight of bovine serum albumin for a sufficient amount of time to enable the albumin to provide a localized anti-inflammatory effect and

removing the albumin from the affected area;

wherein the composition minimizes the removal of protective lipids from the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.

Assignments (5)
SECURITY INTEREST Recorded Apr 15, 2025
From: LIFECYCLE BIOTECHNOLOGIES, LLC
To: BMO BANK N.A., AS AGENT
Reel/Frame 070842/0251 →
CHANGE OF NAME Recorded Mar 21, 2025
From: LIFECYCLE BIOTECHNOLOGIES, LP
To: LIFECYCLE BIOTECHNOLOGIES, LLC
Reel/Frame 070590/0061 →
SECURITY INTEREST Recorded Dec 8, 2023
From: LIFECYCLE BIOTECHNOLOGIES, LLC
To: BMO BANK N.A., AS AGENT
Reel/Frame 065807/0549 →
CHANGE OF NAME Recorded Jan 11, 2017
From: BOVAL COMPANY, LP
To: LIFECYCLE BIOTECHNOLOGIES, LP
Reel/Frame 041328/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2007
From: YARBOROUGH, CODY L.
To: BOVAL COMPANY, L.P.
Reel/Frame 019346/0366 →
Continuity (1)
Related Publication 20080292682A1 · Nov 27, 2008